Compositions and methods for inhibiting MSUT2
Patent Information
- Application Number
- JP2023531075
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-23
- Filing Date
- 2021-11-22
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current interventions for Alzheimer's disease and related dementias are limited to symptom management and do not directly alter tau pathology or neurodegeneration, highlighting the need for disease-modifying therapies that target tau, as evidenced by the failure of amyloid-targeting clinical trials to achieve cognitive preservation.
Development of small interfering RNA (siRNA) molecules that specifically target the mammalian suppressor of tauopathy 2 (MSUT2) gene, reducing its expression and inhibiting its binding to poly(A) RNA, thereby intervening against tauopathies.
The siRNA molecules effectively reduce the accumulation of phosphorylated and aggregated human tau, suppressing MSUT2 expression, and modulating neuroinflammatory responses, thereby potentially slowing or halting the progression of Alzheimer's disease and related dementias.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 117,213, filed November 23, 2020. The contents of this previously filed application are incorporated herein by reference in their entirety.
[0002] Statement Regarding Federally Sponsored Research This invention was made with government support under Grant No. RF1AG055474 awarded by the National Institutes of Health. The government has certain rights in this invention.
[0003] Sequence Listing Reference This application was filed on November 19, 2021, and contains a Sequence Listing submitted via EFS-Web concurrently with the filing of this application, containing filename "37759 0352P1 SL.txt", which is 45,056 bytes in size and is incorporated herein by reference in its entirety. [Background technology]
[0004] The molecular mechanisms underlying neurodegenerative diseases involve cellular disruption of protein homeostasis. In Alzheimer's disease (AD), this disruption manifests as the deposition of amyloid plaques and neurofibrillary tangles (NFTs), which are the diagnostic pathological lesions of this disorder. Although the mechanistic relationship between plaques and neurofibrillary tangles remains unclear, abnormal tau and AP cooperate to cause neurodegeneration in AD. There is a large body of evidence supporting the idea that AP amyloid pathology initiates the disease process in AD. However, the discovery of tau mutations in frontotemporal lobar degeneration involving tau (FTLD-tau) (P. Poorkaj, et al., Ann. Neurol. 43, 815-825 (1998); M. G. Spillantini, et al., Proc. Natl. Acad. Sci. USA 95, 7737-7741 (1998); L. N. Clark, et al., Proc. Natl. Acad. Sci. USA 95, 13103-13107 (1998); and M. Hutton, et al., Nature 393, 702-705 (1998)) indicates that tau pathology can cause neurodegeneration independent of amyloid plaques. Furthermore, tau pathology, unlike amyloid deposition, correlates with the severity of dementia in AD (LM Bierer, et al., Arch Neurol 52, 81-88 (1995)). Thus, findings to date warrant active investigation of the mechanistic basis of both amyloid- and tau-mediated neurodegeneration in AD. Despite a diverse array of highly powered AD clinical trials targeting amyloid production, clearance, or deposition, none have been successful. Overall, these observations suggest that tau-targeting therapies combined with amyloid removal may be required to achieve cognitive preservation in treating AD (MR Khanna, et al., Alzheimer's Dement 12, 1051-1065 (2016) and C. Ballatore, et al., Nat Rev Neurosci 8, 663-672 (2007)). Summary of the Invention
[0005] Provided herein are compositions comprising nucleic acid sequences or molecules, wherein the nucleic acid is: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Disclosed are compositions comprising or consisting of a sequence having the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
[0006] Provided herein are compositions comprising nucleic acid sequences or molecules, wherein the nucleic acid is: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Disclosed are compositions comprising or consisting of a sequence having at least 90% identity to the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
[0007] Disclosed herein is an siRNA molecule, wherein the siRNA molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, and reduces expression of the mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0008] Disclosed herein is a method for treating Alzheimer's disease or dementia, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the therapeutically effective amount reduces the accumulation of phosphorylated, aggregated human tau.
[0009] Disclosed herein is a method for treating Alzheimer's disease or dementia, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the therapeutically effective amount reduces the accumulation of phosphorylated, aggregated human tau.
[0010] Disclosed herein is a method for inhibiting expression of an MSUT2 polynucleotide in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0011] Disclosed herein is a method for inhibiting expression of an MSUT2 polynucleotide in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0012] Disclosed herein is a method for reducing phosphorylated and aggregated human tau protein in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0013] Disclosed herein is a method for reducing phosphorylated and aggregated human tau protein in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0014] Disclosed herein is a method for suppressing expression of an MSUT2 polynucleotide in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0015] Disclosed herein is a method for suppressing expression of an MSUT2 polynucleotide in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0016] Disclosed herein is a method of enhancing a neuroinflammatory response to pathological tau protein in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77 and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0017] Disclosed herein is a method of enhancing a neuroinflammatory response to pathological tau protein in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77 and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0018] Disclosed herein is a method of reducing astrocytosis or microgliosis in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0019] Disclosed herein is a method of reducing astrocytosis or microgliosis in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0020] Disclosed herein is a method of reducing neuroinflammation in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0021] Disclosed herein is a method of reducing neuroinflammation in a subject, the method comprising administering to a subject having Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0022] Disclosed herein is a method of inhibiting expression of an MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
[0023] Disclosed herein is a method of inhibiting expression of an MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the siRNA molecule reduces the accumulation of phosphorylated and aggregated tau.
[0024] Disclosed herein is a method for suppressing expression of an MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
[0025] Disclosed herein is a method for suppressing expression of an MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
[0026] Disclosed herein is a method of enhancing a neuroinflammatory response to pathological tau protein, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77 and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and wherein the siRNA molecule reduces the accumulation of phosphorylated and aggregated tau.
[0027] Disclosed herein is a method of enhancing a neuroinflammatory response to pathological tau protein, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and wherein the siRNA molecule reduces the accumulation of phosphorylated and aggregated tau.
[0028] Disclosed herein is a method of reducing astrocytosis or microgliosis, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and wherein the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0029] Disclosed herein is a method of reducing astrocytosis or microgliosis, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73, and wherein the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0030] Disclosed herein is a method of reducing neuroinflammation, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and wherein the siRNA molecule reduces the accumulation of phosphorylated and aggregated tau.
[0031] Disclosed herein is a method of reducing neuroinflammation, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, and wherein the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0032] Other features and advantages of the compositions and methods of the present invention are set forth in the following description, drawings, and claims. DETAILED DESCRIPTION OF THE INVENTION
[0033] Many modifications and other embodiments of the disclosure described herein will come to mind to one skilled in the art to which this disclosure pertains having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. It is to be understood, therefore, that the disclosure is not limited to the particular embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
[0034] Before the present compositions and methods are disclosed and described, it is to be understood that they are not limited to particular synthetic methods, unless otherwise specified, and are not limited to particular reagents (which, of course, may vary), unless otherwise specified. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods and materials are now described.
[0035] Furthermore, unless expressly stated otherwise, it should be understood that it is in no way intended that any method set forth herein be construed as requiring that its steps be performed in a particular order. Thus, unless a method claim actually recites the order in which its steps are to be followed, or specifically states in the claim or description that the steps are to be limited to a particular order, no order is intended to be inferred in any respect. This holds for any possible implicit basis for interpretation, including the obvious meaning derived from the arrangement of steps or operational flow, grammatical construction or punctuation, and logical matters regarding the number or type of aspects described in the specification.
[0036] All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided herein may be different from the actual publication dates, which may be independently confirmed.
[0037] definition As used in this specification and claims, the term "comprising" can include the aspects "consisting of" and "consisting essentially of." "Comprising" can also mean "including, but not limited to."
[0038] As used in this specification and the appended claims, the singular forms "a," "an," and "the" can include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes mixtures of compounds; reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, etc.
[0039] As used herein, the term "or" means any one member of a particular list and also includes any combination of members of that list.
[0040] As used herein, the term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description is meant to include cases where the event or circumstance occurs and cases where it does not occur.
[0041] As used herein, the term "sample" refers to a tissue or organ from a subject; cells (either within a subject, taken directly from a subject, or cells maintained in culture, or from a cultured cell line); a cell lysate (or lysate fraction) or cell extract; or a solution containing one or more molecules derived from cells or cellular material (e.g., polypeptides or nucleic acids) that are assayed as described herein. A sample may also be any bodily fluid or excretion containing cells or cellular components (e.g., but not limited to, blood, urine, feces, saliva, tears, bile).
[0042] As used herein, the term "subject" refers to the target of administration, e.g., a human. The subject of the disclosed methods can be a vertebrate, such as a mammal, fish, bird, reptile, or amphibian. The term "subject" also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cows, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mice, rabbits, rats, guinea pigs, fruit flies, etc.). In one aspect, the subject is a mammal. In another aspect, the subject is a human. The term does not denote a particular age or sex. Thus, it is intended to encompass adult, child, adolescent, and newborn subjects, as well as fetuses of either sex.
[0043] As used herein, the term "patient" refers to a subject suffering from a disease or disorder. The term "patient" includes human and veterinary subjects. In some aspects of the disclosed methods, the "patient" has been diagnosed as being in need of treatment for Alzheimer's disease or dementia, e.g., prior to the administering step.
[0044] Ranges may be expressed herein as from "about" or "approximately" one particular value and / or to "about" or "approximately" another particular value. When such a range is expressed, a further aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about" or "approximately," it is understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are several values disclosed herein, and that each value is also disclosed herein as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that each unit between two particular units is disclosed. For example, if 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed.
[0045] "Inhibit," "inhibiting," and "inhibition" refer to a decrease or reduction in an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete elimination of the activity, response, condition, or disease. This can also include, for example, a 10% inhibition or reduction of the activity, response, condition, or disease compared to native or control levels. Thus, in certain embodiments, inhibition or reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% reduction compared to native or control levels, or any amount therebetween. In certain embodiments, inhibition or reduction is 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100% reduction compared to native or control levels. In certain aspects, inhibition or reduction is 0-25, 25-50, 50-75, or 75-100% compared to native or control levels.
[0046] As used herein, "modulate," "modulating," and "modulation" refer to a change in activity, function, or number. The change may be an increase or decrease, enhancement, or inhibition of the activity, function, or number.
[0047] As used herein, the term "treating" refers to partially or completely alleviating, mitigating, relieving, delaying the onset of, inhibiting or slowing the progression of, reducing the severity of, and / or reducing the occurrence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. Treatment may be administered to subjects who do not exhibit signs of a disease, disorder, and / or condition and / or who exhibit only early signs of a disease, disorder, and / or condition for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition. Treatment may also be administered to a subject to alleviate one or more symptoms of a disease, disorder, and / or condition. For example, the disease, disorder, and / or condition may be associated with Alzheimer's disease, dementia associated with Alzheimer's disease, or dementia.
[0048] As used herein, the term "nucleic acid" refers to a naturally occurring or synthetic oligonucleotide or polynucleotide capable of hybridizing to a complementary nucleic acid via Watson-Crick base pairing, whether DNA or RNA, or a DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense. The nucleic acids disclosed herein may also contain nucleotide analogs (e.g., BrdU) and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid or thiodiester linkages). In particular, nucleic acids may include, but are not limited to, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA, or any combination thereof.
[0049] The nucleic acid sequences listed herein are written in a 5' to 3' direction unless otherwise specified. The term "nucleic acid" refers to either DNA or RNA, or modified forms thereof that contain purine or pyrimidine bases present in DNA (adenine "A", cytosine "C", guanine "G", thymine "T") or RNA (adenine "A", cytosine "C", guanine "G", uracil "U"). The interfering RNA provided herein may contain a "T" base, for example, at the 3' base, even though the "T" base does not naturally occur in RNA. In some cases, these bases may appear as "dT" to distinguish deoxyribonucleotides present in a chain of ribonucleotides.
[0050] As used herein, the term "complementary" refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid sequence, either by conventional Watson-Crick or other unconventional methods. Percent complementarity indicates the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary).
[0051] As used herein, the term "vector" or "construct" refers to a nucleic acid sequence capable of transporting into a cell another nucleic acid to which the vector sequence has been linked. The term "expression vector" includes any vector (e.g., a plasmid, cosmid, or phage chromosome) that contains a genetic construct in a form suitable for expression by the cell (e.g., linked to transcriptional control or regulatory elements). The terms "plasmid" and "vector" can be used interchangeably, as a plasmid is a commonly used form of vector. Furthermore, the present disclosure is intended to include other vectors that serve equivalent functions.
[0052] All publications and patent applications mentioned in this specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0053] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, certain changes and modifications can be practiced within the scope of the appended claims.
[0054] Tauopathies are a heterogeneous group of neurodegenerative disorders characterized by abnormal metabolism of misfolded i(tau) protein, which leads to the intracellular accumulation and formation of neurofibrillary tangles (NFTs). In Alzheimer's disease (AD), tau neuropathology correlates with the severity of dementia. However, interventions for AD and related dementias are limited to treating symptoms without directly altering tau pathology or the resulting neurodegeneration. This highlights the need for disease-modifying therapies that target tau. Furthermore, results from clinical trials targeting amyloid in AD patients suggest that achieving cognitive preservation in AD may require tau-targeting therapy in combination with amyloid removal. MSUT2 regulates neuronal susceptibility to tau toxicity in the mammalian brain. The mechanism of MSUT2 regulation in tauopathies appears to involve MSUT2 binding to poly(A) RNA and its regulation of RNA polyadenylation. Described herein are siRNAs that inhibit MSUT2 binding to poly(A) RNA, providing a pharmacological means of intervention against tauopathies.
[0055] Targeted reduction of MSUT2 protein has been shown to reverse the toxic consequences of pathological tau in animal models and human cells.Described herein are nucleotide sequences that facilitate gene silencing approaches that target MSUT2, such as RNA-mediated interference and / or antisense oligonucleotides.
[0056] RNA interference (RNAi) is a naturally occurring post-transcriptional regulatory mechanism present in most eukaryotic cells that uses small double-stranded RNA (dsRNA) molecules to direct homology-dependent gene silencing. Shortly after its initial description, RNAi was also shown to occur in mammalian cells via double-stranded small interfering RNAs (siRNAs) 21 nucleotides in length.
[0057] The process of RNA interference is thought to be an evolutionarily conserved cellular defense mechanism used to prevent the expression of foreign genes, is generally shared across diverse phyla and plant species, and is termed post-transcriptional gene silencing.
[0058] The RNAi mechanism is initiated when long double-stranded RNA is processed by an RNase III-like protein known as Dicer. The Dicer protein typically contains an N-terminal RNA helicase domain, an RNA-binding so-called Piwi / Argonaute / Zwille (PAZ) domain, two RNase III domains, and a double-stranded RNA-binding domain (dsRBD) (Collins et al., FEBS Letters, 2005, Vol. 579, Issue 26, pp. 5841-5849). Its activity results in processing of long double-stranded RNA into 21- to 24-nucleotide double-stranded siRNAs with two-base 3' overhangs and 5' phosphate and 3' hydroxyl groups. The resulting siRNA duplexes are then incorporated into an effector complex known as the RNA-induced silencing complex (RISC). The antisense or guide strand of the siRNA guides RISC, which recognizes and cleaves the target mRNA sequence upon ATP-dependent unwinding of the double-stranded siRNA molecule by its RNA helicase activity (Nykanen et al. 2001, Cell, 107(3):309-21). (Elbashir et al. 2001, Nature, 411(6836):494-8). The catalytic activity of RISC, which triggers mRNA degradation, is mediated by the endonuclease Argonaute 2 (AGO2) (Liu et al. 2004, Science, 305(5689):1437-41, and Song et al. 2004, Science, 305:1434-37). AGO2 belongs to the highly conserved Argonaute family of proteins. Argonaute proteins are highly basic proteins of approximately 100 kDa that contain two common domains: the PIWI and PAZ domains (Cerutti et al. 2000, Trends Biochem. Sci. 25(10):481-482). The PIWI domain is important for interaction with Dicer and contains the nuclease activity responsible for mRNA cleavage.AGO2 uses one strand of the siRNA duplex as a guide to find messenger RNA containing the complementary sequence and cleaves the phosphodiester backbone between bases 10 and 11 relative to the 5' end of the guide strand (Elbashir et al. 2001, Nature, 411(6836):494-8). A key step during RISC activation is cleavage of the sense, or passenger, strand by AGO2, removing it from the complex (Rand et al. 2005, Cell, 123(4):621-9). Crystallographic studies analyzing the interactions between the siRNA guide strand and the PIWI domain reveal that the "seed sequence" that directs RISC to the target mRNA consists of approximately 2-8 nucleotides, and that a single nucleotide mismatch within this sequence can dramatically affect the silencing ability of the molecule (Ma et al. 2005, Nature 429, pp. 318-322; Doench et al. 2004, Genes Dev., 18(5):504-11; and Lewis et al. 2003, Cell 115, pp. 787-798). Once mRNA is cleaved, due to the presence of non-conserved RNA ends in the fragment, it is further cleaved and degraded by cellular nucleases and can no longer be translated into protein (Orban et al. 2005, RNA, 11(4):459-469), while RISC is recycled for subsequent rounds (Hutvagner et al. 2002, Science, 297(5589):2056-60). This constitutes a catalytic process that leads to the selective reduction of specific mRNA molecules and corresponding proteins. This natural mechanism for gene silencing can be exploited to regulate any gene of choice by directly delivering siRNA effectors into cells or tissues, which activate RISC and produce potent and specific silencing of targeted mRNAs.
[0059] composition Disclosed herein are target sequences and nucleic acids useful for the methods described herein. In some embodiments, the target sequence may be selected from one or more of the sequences listed in Table 1. In some embodiments, the target may be the MSUT2 gene (also known as ZC3H14). The mouse MSUT2 gene ID is 75553. The human MSUT2 gene ID is 79882. In some embodiments, the target sequence may comprise a fragment of the mRNA MSUT2 sequence. In some embodiments, the target sequence may comprise a fragment of the mRNA MSUT2 sequence, wherein the mRNA MSUT2 sequence comprises a ZF domain. In some embodiments, the target sequence may be SEQ ID NO: 74, or a fragment thereof. In some embodiments, the target sequence may comprise a fragment of SEQ ID NO: 75 or SEQ ID NO: 76. In some embodiments, the target sequence may be SEQ ID NO: 77, or a fragment thereof. In some embodiments, the target sequence may be SEQ ID NO: 78, or a fragment thereof. As used herein, the term "target sequence" as used herein is the target DNA sequence used to define the transcript variant in the database used for the purpose of designing the siRNA, but the particular compound used will be the RNA sequence so defined.
[0060] A gene is "targeted" by an siRNA described herein, for example, when the siRNA molecule selectively reduces or inhibits the expression of the gene. The phrase "selectively reduces or inhibits" as used herein encompasses siRNAs that affect the expression of a single gene, in this case, MSUT2. Alternatively, an siRNA targets a gene when (one strand of) the siRNA hybridizes to the gene transcript, i.e., its mRNA, under stringent conditions. Hybridizing "under stringent conditions" means annealing to the target sequence under standard conditions, e.g., high temperature and / or low salt content, which tend to interfere with hybridization. A suitable protocol (including 0.1×SSC at 68°C for 2 hours) is described in Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, on pages 387-389.
[0061] In some embodiments, the target sequence may include the MSUT2 ZF domain, or a portion or part of the MSUT2 ZF domain. The ZF domain is the functional part of the MSUT2 protein that binds to poly(A) RNA. Short isoforms of the MSUT2 protein encode the ZF domain. Long isoforms of the MSUT2 protein may have additional domains. Targeting other domains allows the short isoform to continue to perform the MSUT2 RNA-binding function. In some embodiments, to achieve a strong loss of function, the siRNA sequence can target the MSUT2 ZF domain.
[0062] In some embodiments, the target sequences described herein may comprise or consist of at least one sequence selected from SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:74 to SEQ ID NO:76, SEQ ID NO:77, and SEQ ID NO:78. [Table 1]
[0063] The longest encoded mRNA for mouse 4 protein is NM 029334.2→NP 083610.2 (SEQ ID NO: 75). [Sequence Table 1] TIFF2023551223000002.tif198123
[0064] The longest coding mRNA in humans is NM_024824.5-+NP_079100.2 (SEQ ID NO: 76). [Sequence Table 2] TIFF2023551223000003.tif160125 TIFF2023551223000004.tif239126 TIFF2023551223000005.tif241121 TIFF2023551223000006.tif240127 TIFF2023551223000007.tif102130
[0065] Disclosed herein are siRNA molecules. Also disclosed herein are compositions comprising any of the siRNA molecules described herein or listed in Table 2. In some embodiments, the siRNA molecule can be a sense strand. In some embodiments, the siRNA molecule can be an antisense strand.
[0066] Provided herein are compositions comprising nucleic acid sequences or molecules, wherein the nucleic acid is: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Disclosed are compositions comprising or consisting of a sequence having the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
[0067] Provided herein is a composition comprising a nucleic acid sequence or molecule, wherein the nucleic acid is UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Disclosed are compositions comprising or consisting of a sequence having at least 90% identity to the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73). [Table 2] TIFF2023551223000009.tif156141
[0068] In some embodiments, the siRNA molecule may comprise a double-stranded RNA molecule. In some embodiments, the siRNA molecule may comprise a double-stranded RNA molecule, the antisense strand of which comprises an RNA sequence substantially complementary to at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, or SEQ ID NO:78, and the sense strand of which comprises an RNA sequence complementary to the antisense strand, and both strands are hybridized by standard base pairing between nucleotides. In some embodiments, the siRNA molecule may comprise a double-stranded RNA molecule, the antisense strand of which will comprise an RNA sequence substantially complementary to SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, or SEQ ID NO:78.
[0069] As used herein, "substantially complementary" to a target mRNA sequence can also be understood as "substantially identical" to the target sequence. "Identity" refers to the degree of sequence relatedness between nucleotide sequences, as determined by matching the order and identity of nucleotides between sequences. In some embodiments, the antisense strand of an siRNA having 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% complementarity to a target mRNA sequence is considered to be substantially complementary and can be used in the present invention. The percentage of complementarity describes the percentage of consecutive nucleotides in a first nucleic acid molecule that can form base pairs in Watson-Crick terms with a set of consecutive nucleotides in a second nucleic acid molecule. In some embodiments, the antisense siRNA strand is 100% complementary to the target mRNA sequence, and the sense strand is 100% complementary to the antisense strand across the double-stranded portion of the siRNA. The siRNA may also include an unpaired overhang, such as a 3' dinucleotide overhang, and in some embodiments, dTdT.
[0070] Generally, double-stranded molecules can be about 19 to about 25 nucleotides in length, including those with blunt-ended structures and overhangs. Overhangs have been described as advantageous and can be present at the 5' or 3' end of either strand to reduce recognition by RNAses and mimic the natural substrates of Dicer. In some embodiments, overhangs can be present at both 3' ends of the molecule. In some embodiments, one overhang is present at one end of the molecule. Others have described the use of blunt-ended structures with specific modification patterns (EP1527176, WO2005062937, WO2008104978, EP2322617, EP2348133, US20130130377, and many others).
[0071] The overhang may contain 1 to 5 nucleotides, and typically, the overhang is composed of a dinucleotide. Classical molecules used in this field include 19-nucleotide double-stranded molecules, which further include a 3' dinucleotide overhang, preferably a deoxynucleotide, as taught in the early work by Tuschl (WO0244321). These overhangs are said to further enhance resistance to nuclease (RNase) degradation. Subsequently, Kim et al. (2005) (Kim et al., Nat. Biotechnol. 2005, Feb;23(2):222-6) described that the 21-mer product (containing a dinucleotide overhang) is important for loading into the RNA-induced silencing complex (RISC). Furthermore, Bramsen et al. 2009 (Bramsen et al. Nucleic Acids Res. 2009, May; 37(9):2867-81) describe the introduction of possible destabilizing modifications to the overhangs to further increase silencing efficiency.
[0072] In some embodiments, the siRNA molecules described herein may target at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, comprising at least one overhang, preferably a 3' overhang, in the sense and / or antisense strand. In some embodiments, the siRNA molecule targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, or SEQ ID NO:78, and the siRNA may comprise an antisense strand of equal length and complementary to the target and a sense strand of equal length and complementary to the antisense strand. The antisense and sense strands may further comprise additional bases that are not complementary to the other strand or to the target and / or are not paired in the double-stranded portion of the siRNA.
[0073] In some embodiments, the siRNA molecule described herein targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, wherein each strand of the double-stranded siRNA molecule is about 18 to about 28, or longer, nucleotides in length (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28, or longer).
[0074] Disclosed herein is an siRNA molecule, which specifically targets a sequence comprising or consisting of a sequence of SEQ ID NO: 1, 2, 3, 4, 5, 77, or 78, and reduces expression of the mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence having at least 90% sequence identity to a sequence comprising a sequence of SEQ ID NO: 6 to SEQ ID NO: 73.
[0075] In some embodiments, the siRNA molecule described herein comprises 18 to 28 or more nucleotides in length and comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule described herein comprises 18 to 28 or more nucleotides in length and comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, and 73. In some embodiments, the double-stranded siRNA molecule is at least 19 nucleotides in length and may be selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.
[0076] Also described herein are blunt-ended molecules. Disclosed herein are siRNA molecules that specifically target at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78. In some embodiments, the siRNA molecule can reduce expression of the mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 18 to 28 nucleotides, 19 to 25 nucleotides, or 25 to 28 nucleotides. In some embodiments, the siRNA molecule comprises at least one sequence having at least 90% sequence identity selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule comprises at least one sequence having at least 90% sequence identity selected from the group consisting of SEQ ID NOs: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, and 73.
[0077] In some embodiments, the siRNA molecule comprises a 19-nucleotide double-stranded blunt-ended siRNA targeted to at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78. In some embodiments, the siRNA molecule comprises or consists of at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the antisense strand of this siRNA is at least 80%, at least 90% complementary to at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78.
[0078] In some embodiments, the siRNA molecules disclosed herein may comprise or consist of at least one sequence selected from the group consisting of SEQ ID NO: 6 through SEQ ID NO: 73. In some embodiments, the siRNA molecules disclosed herein may comprise or consist of at least one sequence selected from the group consisting of SEQ ID NO: 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, and 73.
[0079] In some embodiments, the siRNA molecules disclosed herein may comprise or consist of a sense strand comprising or consisting of at least one sequence selected from the group consisting of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, and 72, and an antisense strand that is complementary to the sense strand.
[0080] Due to the ubiquity of RNAse, siRNA molecule may be unstable in biological fluid.Therefore, many different chemical modifications have been described for nucleotide to enhance the stability of compound.Disclosed herein is the siRNA molecule that is stable in biological fluid.
[0081] siRNA molecules may also be immunogenetic and have in some cases been found to induce non-specific activation of the innate immune system, including the upregulation of certain cytokines.
[0082] Furthermore, both of these effects (RNase recognition and immunogenicity) have been described to be sequence dependent.
[0083] This document describes chemical modifications that can enhance or can enhance the stability of siRNA molecules.In some embodiments, chemical modifications can increase or enhance the stability of siRNA molecules by reducing their susceptibility to RNAse, thereby reducing the induction of immune recognition and therefore reducing the subsequent immune response.
[0084] In some embodiments, the siRNA molecules described herein may further comprise at least one nucleotide having a chemical modification. In some embodiments, at least one nucleotide of the siRNA molecule may comprise a chemical modification.
[0085] In some embodiments, chemical modifications that enhance stability and reduce immunogenic effects may include, but are not limited to, 2'-0-methyl nucleotides, 2'-fluoro nucleotides, 2'-amino nucleotides, 2'-deoxy nucleotides, or nucleotides containing 2'-0 or 4'-C methylene bridges. Examples of chemical modifications for exonuclease protection include, but are not limited to, the ExoEndoLight (EEL) pattern of modifications, such as pyrimidines in the sense strand being replaced with 2'-0-methyl residues, and pyrimidines in 5'-UA-3' or 5'-CA-3' motifs being replaced with 2'-0-methyl residues in the antisense strand. In some embodiments, position 1 of the sense strand may be modified to 2'-0-methyl to prevent 5'-phosphorylation of the sense strand and thus increase the strand specificity of the siRNA. In addition, the sense strand may also include a 2'-0-methyl modification at position 14, because the 2'-0-Me residue at this position inactivates the sense strand, thereby increasing the strand specificity of the siRNA molecule. Further examples of chemical modifications for nuclease protection include, but are not limited to, methyl-fluoro modification patterns (MEF) (alternating 2'-fluoro and 2'-O-methyl modifications, starting with 2'-F on the sense strand (5'-end) and 2'-O-Me on the antisense strand). In some embodiments, position 1 of the sense strand can be modified to 2'-O-Me, and position 1 of the antisense strand can be modified to 2'-F (because 2'F residues are compatible with 5'-phosphorylation, while 2'O-Me residues are bulky and generally interfere with phosphorylation). This modification pattern can stabilize the molecule and negate the ability of RISC to use the sense strand, thus promoting strand specificity. Additionally, modifications to the ribonucleotide backbone can be achieved by linking nucleotides using phosphorothioate linkages instead of phosphodiester linkages. In some embodiments, the chemical modification can be a substitution of uracil ribonucleotides with 4' thioribose, 5-propynyluracil 3',5'-methyluridine, or deoxythymidine (deoxyribonucleotides).
[0086] In some embodiments, the chemical modification may include one or more amino acids bearing an amino acid, carbohydrate, or lipid moiety.
[0087] In some embodiments, at least one chemically modified nucleotide in the ribonucleotide backbone and / or at least one chemical modification is on the sense strand, the antisense strand, or both strands of the siRNA molecule. In some embodiments, the chemical modification is on the sense strand, the antisense strand, or both strands of the siRNA molecule.
[0088] In some embodiments, the siRNA molecule may comprise or consist of at least one sequence having a sense strand and / or an antisense strand selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise or consist of at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.
[0089] In some embodiments, the siRNA molecule may comprise or consist of a sense strand comprising or consisting of at least one sequence selected from the group of: SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72.
[0090] In some embodiments, the siRNA molecule may comprise or consist of an antisense strand that is complementary to a sense strand selected from the group of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:73.
[0091] In some embodiments, the siRNA molecule is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 The nucleic acid sequence may comprise or consist of a sense strand comprising or consisting of at least one sequence selected from the group of SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72, and an antisense strand which is complementary to the sense strand selected from the group of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:73.
[0092] Any of the compositions disclosed herein may further comprise a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier for the siRNA molecule may be buffered saline. In some embodiments, the pharmaceutically acceptable carrier may comprise a lipid-based or polymer-based colloid. In some embodiments, the colloid may be a liposome, a hydrogel, a microparticle, a nanoparticle, or a block copolymer micelle. In some embodiments, the compositions described herein may be formulated for intravenous, subcutaneous, intrathecal, intramuscular, oral, intrathecal, or intraperitoneal administration. In some embodiments, a therapeutically effective amount of any of the siRNA molecules disclosed herein reduces the accumulation of phosphorylated, aggregated human tau.
[0093] The siRNA molecules described herein can be delivered into cells in their natural structure using methods known in the art.In some embodiments, siRNA molecules can be administered using standard transfection reagents.To achieve in vivo effects, these siRNA molecules can also be administered naked or in combination with specific moieties using delivery enhancers such as liposomes, although many different alternatives are known in the art and are used in different ways depending on the desired target site in the body.
[0094] In some embodiments, the siRNA molecules described herein can be expressed intracellularly from a eukaryotic promoter. Recombinant vectors capable of expressing siRNA molecules can be delivered and persist in target cells. Alternatively, vectors that provide transient expression of nucleic acid molecules can be used. Such vectors can be administered repeatedly as needed. Upon expression, the siRNA molecules interact with target mRNA and generate an RNA interference response. The siRNA molecules produced in this manner are often referred to as shRNAs (short hairpin RNAs) because their sense and antisense strands are connected by a small loop of nucleotides. Delivery of vectors expressing siRNA molecules can also be systemic, for example, by intravenous or intramuscular administration, by administration to target cells explanted from a subject and then reintroduced into the subject, or by any other means that allows introduction into the desired target cells.
[0095] Also disclosed is the use of an siRNA targeting at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77, and SEQ ID NO: 78 in the preparation of a medicament for use in a method for treating Alzheimer's disease or dementia characterized by increased expression and / or activity of MSUT2. In some embodiments, the use comprises inhibiting expression of MSUT2 polynucleotide in a subject. The term inhibit is used to indicate a decrease or downregulation of expression or activity. In some embodiments, Alzheimer's disease or dementia may be associated with or related to an increase in phosphorylated or aggregated tau protein.
[0096] Treatment method The methods disclosed herein may be useful for treating subjects with Alzheimer's disease or dementia. In some embodiments, the siRNA molecule can enhance the neuroinflammatory response to pathological tau. In some embodiments, the siRNA molecule can reduce astrocytosis or microgliosis. In some embodiments, the siRNA molecule can reduce neuroinflammation. In some embodiments, the siRNA molecule can inhibit expression of a MUST2 polynucleotide. In some embodiments, the siRNA molecule can reduce the accumulation of phosphorylated and aggregated human tau.
[0097] In some embodiments, the methods may include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule, or a composition comprising an siRNA molecule, that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the therapeutically effective amount is capable of reducing the accumulation of phosphorylated, aggregated human tau.
[0098] In some embodiments, the methods may include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule, or a composition comprising the siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the therapeutically effective amount is capable of reducing the accumulation of phosphorylated, aggregated human tau.
[0099] The methods disclosed herein may be useful for inhibiting expression of MSUT2 polynucleotides. In some embodiments, the methods can inhibit expression of MSUT2 polynucleotides in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule specifically targeting at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73, SEQ ID NO:77, and SEQ ID NO:78. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0100] The methods disclosed herein may be useful for inhibiting expression of MSUT2 polynucleotide. In some embodiments, the method can inhibit expression of MSUT2 polynucleotide in a subject. The method may include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to the sequences of SEQ ID NO:6 to SEQ ID NO:73, SEQ ID NO:77, and SEQ ID NO:78. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated and aggregated human tau.
[0101] The methods disclosed herein can be useful for reducing the accumulation of phosphorylated, aggregated human tau protein in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule, or a composition comprising an siRNA molecule, that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1-5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0102] The methods disclosed herein can be useful for reducing the accumulation of phosphorylated, aggregated human tau protein in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule, or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence of SEQ ID NO:6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO:6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0103] The methods disclosed herein may be useful for suppressing expression of MSUT2 polynucleotides. In some embodiments, the methods can suppress expression of MSUT2 polynucleotides in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule specifically targeting at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0104] The methods disclosed herein may be useful for suppressing expression of MSUT2 polynucleotide. In some embodiments, the method can suppress expression of MSUT2 polynucleotide in a subject. The method may include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from SEQ ID NOs: 6 to 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 6 to 73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated and aggregated human tau.
[0105] The methods disclosed herein may be useful for enhancing a neuroinflammatory response to pathological tau protein. In some embodiments, the methods can enhance a neuroinflammatory response to pathological tau protein in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0106] The methods disclosed herein may be useful for enhancing a neuroinflammatory response to pathological tau protein. In some embodiments, the methods can enhance a neuroinflammatory response to pathological tau protein in a subject. The methods may include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0107] The methods disclosed herein may be useful for reducing astrocytosis or microgliosis. In some embodiments, the methods can reduce astrocytosis or microgliosis in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0108] The methods disclosed herein can be useful for reducing astrocytosis or microgliosis. In some embodiments, the methods can reduce astrocytosis or microgliosis in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0109] The methods disclosed herein may be useful for reducing neuroinflammation. In some embodiments, the methods can reduce neuroinflammation in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, or a composition comprising the siRNA molecule. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0110] The methods disclosed herein can be useful for reducing neuroinflammation. In some embodiments, the methods can reduce neuroinflammation in a subject. The methods can include administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising an siRNA molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NOs: 6-73. In some embodiments, the therapeutically effective amount can reduce the accumulation of phosphorylated, aggregated human tau.
[0111] In some embodiments, the subject has Alzheimer's disease. In some embodiments, the subject has dementia. In some embodiments, the subject has mild to moderate Alzheimer's disease. In some embodiments, the subject has moderate to severe Alzheimer's disease. Alzheimer's disease typically progresses slowly through three general stages: mild (early), moderate (mid-stage), and severe (late-stage). In mild Alzheimer's disease (early stage), the subject is still able to function independently but may notice memory impairments, such as forgetting the location of familiar words or everyday objects. During moderate Alzheimer's disease (mid-stage), the subject may have significant difficulty performing tasks (e.g., paying the bill) and may have speech confusion, but will still remember important details about their life. In addition, subjects at this stage may become moody or withdrawn, have an increased risk of wandering and getting lost, and may exhibit personality and behavioral changes, including distrust and delusions, or compulsive repetitive behaviors. In severe (late) Alzheimer's disease, subjects lose the ability to respond to their environment, to communicate, and ultimately to control their movements. Also, in this severe stage, subjects require extensive assistance with daily activities and communication becomes increasingly difficult.
[0112] In some embodiments, the subject has Alzheimer's-associated dementia. In some embodiments, the Alzheimer's-associated dementia can be progressive supranuclear palsy, chronic traumatic encephalopathy, frontotemporal lobar degeneration, or other tauopathy disorders. The methods disclosed herein can be effective in targeting one or more genes, including mammalian suppressor of tauopathy 2 (MSUT2).
[0113] In some embodiments, the method also includes administering a therapeutically effective amount of any of the siRNA molecules disclosed herein. In some embodiments, the siRNA molecule comprises or consists of a sense strand comprising or consisting of at least one sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72.
[0114] In some embodiments, the siRNA molecule comprises, or consists of, an antisense strand comprising, or consisting of, at least one sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65 SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:73.
[0115] In some embodiments, the siRNA molecule is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 and an antisense strand that is complementary to the sense strand selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:73.
[0116] In some embodiments, a method of treating a subject can include contacting a cell or a subject with an effective amount of a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0117] In some embodiments, methods of treating a subject may include contacting a cell or a subject with an effective amount of a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0118] Disclosed herein are methods for inhibiting expression of MSUT2 polynucleotides. In some embodiments, the methods can include contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1-5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0119] In some embodiments, the method may include contacting the cell with a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0120] Disclosed herein are methods for suppressing expression of MSUT2 polynucleotides. In some embodiments, the methods may include contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1 to 5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6 to 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6 to 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0121] In some embodiments, the method may include contacting the cell with a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0122] Disclosed herein are methods of enhancing a neuroinflammatory response to pathological tau protein. In some embodiments, the methods can include contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1-5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0123] In some embodiments, the method may include contacting the cell with a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0124] Disclosed herein are methods for reducing astrocytosis or microgliosis. In some embodiments, the methods can include contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1-5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0125] In some embodiments, the method may include contacting the cell with a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0126] Disclosed herein are methods for reducing neuroinflammation. In some embodiments, the methods can include contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NOs: 1-5, 77, and 78. In some embodiments, the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule can comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 6-73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0127] In some embodiments, the method may include contacting the cell with a small interfering RNA (siRNA) molecule, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from SEQ ID NO: 6 to SEQ ID NO: 73. In some embodiments, the siRNA molecule reduces the accumulation of phosphorylated, aggregated tau.
[0128] In some aspects, the cell can be a vertebrate, mammalian, or human cell. In some aspects, the cell can be a brain cell. In some aspects, the cell can be a mammalian cell. In some aspects, the mammalian cell can be a brain cell.
[0129] In some embodiments, at least one nucleotide of any of the siRNA molecules may contain a chemical modification. In some embodiments, the chemical modification may be on the sense strand, the antisense strand, or both strands. In some embodiments, the siRNA molecule may contain at least one sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73. In some embodiments, the siRNA molecule may contain at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:73.
[0130] In some embodiments, the method may further include identifying a subject (e.g., a human patient) with Alzheimer's disease or dementia, and then providing the subject with any of the siRNA molecules disclosed herein or a composition comprising any of the siRNA molecules disclosed herein. In some embodiments, the small interfering RNA (siRNA) molecule or composition comprising the siRNA molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, and the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73. In some embodiments, the siRNA molecule may comprise at least one sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NO:6-73.
[0131] In some embodiments, the subject has Alzheimer's-related dementia. In some embodiments, the Alzheimer's-related dementia can be progressive supranuclear palsy, chronic traumatic encephalopathy, frontotemporal lobar degeneration, or other tauopathy disorders. In some embodiments, the subject can be identified using standard clinical tests known to those skilled in the art. Although a definitive AD diagnosis requires a postmortem examination, a skilled physician can assess cognitive function with greater than 95% accuracy. Examples of tests for diagnosing Alzheimer's disease or dementia include the Mini-Mental State Examination (MMSE), Mini-cognitive score (copyright), Alzheimer's Disease Composite Score (ADCOMS), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Clinical Dementia Rating Scale-SB (CDR-SB).
[0132] A therapeutically effective amount may be the amount of composition administered to a subject that results in complete elimination of symptoms of a condition or disease, reduction in the severity of symptoms of a condition or disease, or delay in the progression of symptoms of a condition or disease. The methods described herein may also include a monitoring step to optimize dosing. The compositions described herein can be administered as a preventative treatment or to slow or delay the progression of degenerative changes. In some embodiments, a therapeutically effective amount of any of the siRNA molecules disclosed herein can reduce the accumulation of phosphorylated and aggregated human tau.
[0133] The compositions disclosed herein can be used in a variety of ways. For example, the compositions disclosed herein can be used for the direct delivery of modified therapeutic cells or adeno-associated viruses. The compositions disclosed herein can be used, delivered, or administered at any time during the treatment process. The compositions described herein, including cells or viruses, can be delivered to one or more brain regions, one or more brain cells, or brain regions or brain cells to stop or prevent one or more symptoms of a disease or condition in adjacent brain regions or brain cells.
[0134] The administered dosage depends on many factors, including, for example, the route of administration, the formulation, the severity of the patient's condition / disease, previous treatments, the patient's size, weight, surface area, age, and sex, other drugs administered, and the patient's overall general health, including the presence or absence of other diseases, disorders, or conditions. Dosage levels can be adjusted using standard empirical methods for optimization known to those of skill in the art. The compositions described herein can be administered single or multiple times (e.g., two, three, four, six, eight, ten, twenty, fifty, one hundred, one hundred, one hundred and fifty, or more). Furthermore, the efficiency of delivery can be improved by encapsulating the composition in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices).
[0135] A therapeutically effective amount of a composition described herein can include a single treatment or a series of treatments (i.e., multiple treatments or administered multiple times). The duration of treatment using any of the compositions disclosed herein can be any length of time, for example, from one day to the life of the subject (e.g., several years). For example, the composition can be administered once daily, once weekly, once monthly, or once yearly for five, ten, or more years. The frequency of treatment can vary. For example, the compositions described herein can be administered once daily, once weekly, once monthly, or once yearly (or twice, three times, etc.) for five, ten, or more years.
[0136] In some embodiments, the compositions disclosed herein can also be co-administered with other therapeutic agents. In some embodiments, the methods disclosed herein can further include administering a cholinesterase inhibitor to the subject. In some embodiments, the cholinesterase inhibitor can be galantamine, rivastigmine, or donepezil. In some embodiments, the methods disclosed herein can further include administering an anti-inflammatory therapy to the subject.
[0137] In some embodiments, the methods disclosed herein also include treating a subject with Alzheimer's disease or dementia. In some embodiments, the methods disclosed herein may include determining the MSUT2 level in the subject.
[0138] Pharmaceutical Compositions As disclosed herein, pharmaceutical compositions include compositions disclosed herein.In some embodiments, pharmaceutical compositions can include any of the siRNA molecules disclosed herein.In some embodiments, compositions can include at least one siRNA molecule disclosed herein.In some embodiments, pharmaceutical compositions can further include a pharmaceutically acceptable carrier.
[0139] Provided herein is a pharmaceutical composition comprising a nucleic acid sequence or molecule, wherein the nucleic acid is: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Pharmaceutical compositions are disclosed that comprise or consist of a sequence having the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
[0140] Provided herein is a pharmaceutical composition comprising a nucleic acid sequence or molecule, wherein the nucleic acid is: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19). CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25) UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAGA (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO: 51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO: 53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO: 55), GUGGUGCUGGUGGUGCAACUGGUUUUGG (SEQ ID NO: 57), ACGGCAGAGCUGACUACUGGAAGGUGGU (SEQ ID NO: 59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO: 69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or Pharmaceutical compositions are disclosed that comprise or consist of a sequence having at least 90% identity to the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
[0141] As used herein, the term "pharmaceutically acceptable carrier" refers to solvents, dispersion media, coatings, antibacterial agents, isotonic and absorption delaying agents, buffers, excipients, binders, lubricants, gels, and surfactants that can be used as vehicles for pharmaceutically acceptable substances. Pharmaceutically acceptable carriers can be lipid-based or polymer-based colloids. Examples of colloids include liposomes, hydrogels, microparticles, nanoparticles, and micelles. The compositions can be formulated for administration by any of a variety of routes and may contain one or more physiologically acceptable excipients, which may vary depending on the route of administration. Any of the nucleic acids, vectors, siRNAs, antisense siRNAs, and sense siRNAs described herein can be administered in the form of a pharmaceutical composition.
[0142] As used herein, the term "excipient" means any compound or substance, including those that may also be referred to as "carriers" or "diluents." Preparing pharmacologically and physiologically acceptable compositions is deemed routine in the art, and, accordingly, those skilled in the art can consult numerous authorities for guidance as necessary. The compositions may also include additional agents (e.g., preservatives).
[0143] The pharmaceutical compositions disclosed herein can be prepared for oral or parenteral administration. Pharmaceutical compositions prepared for parenteral administration include those prepared for intravenous (or intraarterial), intramuscular, subcutaneous, intrathecal, or intraperitoneal administration. Parenteral administration can be in the form of a single bolus dose or, for example, via a continuous pump. In some embodiments, the composition can be prepared for parenteral administration by dissolving or suspending the nucleic acid, polynuclear sequence, vector, or siRNA molecule in an acceptable carrier, including, but not limited to, an aqueous carrier, such as water, buffered water, saline, buffered saline (e.g., PBS), etc. One or more of the included excipients can help approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents, etc. When the composition includes solid components (which may be for oral administration), one or more of the excipients can function as a binder or filler (e.g., for the formulation of tablets, capsules, etc.). Where the composition is formulated for application to the skin or a mucosal surface, one or more of the excipients may be a solvent or emulsifier, for the formulation of a cream, ointment, or the like.
[0144] In some aspects, the compositions disclosed herein are formulated for oral, intramuscular, intravenous, subcutaneous, intrathecal, or intraperitoneal administration.
[0145] Pharmaceutical compositions may be sterilized by conventional sterilization techniques or may be sterile filtered. Aqueous solutions may be packaged for immediate use, or lyophilized lyophilized preparations encompassed by the present disclosure may be combined with a sterile aqueous carrier prior to administration. The pH of pharmaceutical compositions will typically be 3-11 (e.g., about 5-9) or 6-8 (e.g., about 7-8). Compositions obtained in solid form may be packaged in multiple single-dose units, each containing a predetermined amount of one or more of the above-mentioned agents (e.g., sealed packages of tablets or capsules). Solid forms of compositions may also be packaged in flexible-quantity containers, such as compressible tubes designed for topically applied creams or ointments. Compositions may also be formulated as powders, elixirs, suspensions, emulsions, solutions, syrups, aerosols, lotions, creams, ointments, gels, suppositories, sterile injectable solutions, and sterile-packaged powders. The active ingredient may be an siRNA molecule, nucleic acid, or vector described herein, combined with one or more pharmaceutically acceptable carriers. As used herein, "pharmaceutically acceptable" refers to molecules and compositions that, when administered to a subject as intended (i.e., as appropriate), do not produce or cause an adverse reaction (i.e., an adverse, negative, or allergic reaction).
[0146] In some embodiments, the vectors, siRNAs, and nucleic acid sequences disclosed herein can be delivered to cells of a subject, hi some embodiments, such can be achieved, for example, by using polymeric, biodegradable microparticle, or microcapsule delivery vehicles sized to optimize phagocytosis by phagocytic cells (e.g., macrophages).
[0147] In some embodiments, the formulation comprises a virus (e.g., adeno-associated virus) and any suitable for delivery of cells. In some embodiments, the route of administration includes, but is not limited to, direct injection into the brain. Such administration can be performed without surgery or in conjunction with surgery.
[0148] kit Disclosed herein are kits comprising any combination of the above-described compositions (e.g., any of the siRNAs) and suitable instructions (e.g., described and / or provided as audio, visual, or audiovisual materials). Disclosed herein are kits comprising any combination of the above-described pharmaceutical compositions and suitable instructions (e.g., described and / or provided as audio, visual, or audiovisual materials). In some embodiments, the kits comprise a predetermined amount of a composition or pharmaceutical composition comprising any of the siRNA molecules disclosed herein. The kits may further comprise one or more of instructions, sterile fluids, syringes, sterile containers, delivery devices, and buffers or other control reagents. [Example]
[0149] Example 1: Targeted nucleic acid sequences for silencing MSUT2 / ZC3H14 HEK293 cells were cultured under standard tissue culture conditions (DMEM, 10% defined fetal bovine serum, penicillin (1000 IU / mL), streptomycin (1000 mg / mL) (Wheeler et al., Science Translational Medicine, 2019 Dec. 18; 11(253)). RNA interference transfection was performed according to the manufacturer's protocol (RNAiMAX, Invitrogen). Cell pellet lysates were prepared for immunodetection (Wheeler et al., Science Translational Medicine, 2019 Dec. 18; 11(253)). Lysates were diluted with 0.1x sample buffer (1:25, Protein Simple) and analyzed by Peggy Sue (Protein Simple) using a 12-230 kDa capillary according to the manufacturer's protocol. MSUT2 was detected using Antibody Diluent 2 (Protein Simple). Antibodies were detected with Rbt9857 antibody (Wheeler, et al. 2019 (STM)) diluted 1:10 in Simplex (Simplex), and actin was detected using A4700 (Sigma-Aldrich) diluted 1:200. Goat anti-rabbit secondary antibody (GE Lifescience) was diluted 1:100 in Antibody Diluent 2. MSUT2 knockdown was analyzed by peak height and peak area normalized to actin.
[0150] To measure the efficacy of siRNA treatment, synthetic siRNA was introduced into HEK293 cells using Lipofectamine RNAimax Reagent (Thermo) according to the manufacturer's instructions. Three days after transfection, siRNA-treated cells were harvested and analyzed for MSUT2 protein levels using a ProteinSimple capillary immunoassay. MSUT2 protein levels were expressed as a percentage of endogenous MSUT2 levels compared with MSUT2 siRNA- and mock-treated cells. The results are shown in Table 3. [Table 3] TIFF2023551223000011.tif208144 TIFF2023551223000012.tif208141 TIFF2023551223000013.tif125142
Claims
1. A composition comprising a nucleic acid sequence or molecule, said nucleic acid comprising: UUUUCUGGUUUCUGUGCCACACUCAGU (SEQ ID NO: 7), UUUUUCUGGUUUCUGUGCCACACUCAG (SEQ ID NO: 9), GUUUUUCUGGUUUCUGUGCCACACUCA (SEQ ID NO: 11), AGUUUUUCUGGUUUCUGUGCCACACUC (SEQ ID NO: 13), AAGUUUUUCUGGUUUCUGUGCCACACU (SEQ ID NO: 15), GCAGGCCAGUACUUGCAGCGCUCCAAA (SEQ ID NO: 17), AAGCAGGGAAGUAACGGCAGAGCUGAC (SEQ ID NO: 19), CAAGCAGGGAAGUAACGGCAGAGCUGA (SEQ ID NO: 21), ACAAGCAGGGAAGUAACGGCAGAGCUG (SEQ ID NO: 23), UACAAGCAGGGAAGUAACGGCAGAGCU (SEQ ID NO: 25), UUACAAGCAGGGAAGUAACGGCAGAGC (SEQ ID NO: 27), CUUACAAGCAGGGAAGUAACGGCAGAG (SEQ ID NO: 29), UCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 31), UUCUUACAAGCAGGGAAGUAACGGCAG (SEQ ID NO: 33), CACUCAUCUCAGCGUUAGAAAGCUACC (SEQ ID NO: 35), UCUGGUUUCUGUGCCACACUCAGUUCAC (SEQ ID NO: 37), UACUUGCAGCGCUCCAAAAGUUUUUCUG (SEQ ID NO: 39), UCCCCAUUUUUACAAGCAGGCCAGUACU (SEQ ID NO: 41), GAUGGGGUGAUGGUAGGCACACUCAUCC (SEQ ID NO: 43), UUGGGGAAGGCUUUGCAGGGUGAGAUGG (SEQ ID NO: 45), AAACAUUUUUCAGCAAAUUUACAAUUGG (SEQ ID NO: 47), UAUUUACAAUUUGGGGUGAACAAACAAAC (SEQ ID NO: 49), UCUGGUUUAGUACACUUUGCAUCAUAUU (SEQ ID NO:51), UACUCACAUGAGUGAAGGGACAAUCUGG (SEQ ID NO:53), UUGGAGACAGUACUGGAAUUCUUCUACU (SEQ ID NO:55), GUGGUGCUGGUGGUGGUGCAACUGGUUUUGG (SEQ ID NO:57), ACGGCAGAGCUGACUACUGGAAGGGUGGU (SEQ ID NO:59), CCAUCUUCUUACAAGCAGGGAAGUAACGG (SEQ ID NO: 61), GUUUUGGAUGAUAGAAGGGACAUUCCAU (SEQ ID NO: 63), UACAUUGAGUGUAAACCUACAAUGUUU (SEQ ID NO: 65), GUAGAAUGUGCAGUCCGGUCUUGUACAU (SEQ ID NO: 67), UGGUGGGACAUUAAUGGUGGGAUGGUAG (SEQ ID NO:69), UCGAAUCCAUUUCAAGGCAUGUCGUGGU (SEQ ID NO: 71), or A composition comprising or consisting of a sequence having at least 90% identity to the sequence set forth in UUAUUCGCUGGUUUGAGGUCGAAUCCAU (SEQ ID NO: 73).
2. 1. An siRNA molecule, wherein the siRNA molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:5, SEQ ID NO:77, and SEQ ID NO:78, and reduces expression of a mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25 to 28 nucleotides, and wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity selected from the group consisting of SEQ ID NO:6 to SEQ ID NO:
73.
3. The siRNA molecule of claim 2 , wherein at least one nucleotide of the siRNA molecule comprises a chemical modification.
4. The siRNA molecule of claim 3 , wherein the chemical modification is on the sense strand, the antisense strand, or both strands of the siRNA molecule.
5. The siRNA molecule of claim 2, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO:
73.
6. the siRNA molecule is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 3. The siRNA molecule of claim 2, comprising or consisting of a sense strand comprising or consisting of at least one sequence selected from the group of SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72, and an antisense strand which is complementary to the sense strand selected from the group of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:
73.
7. A pharmaceutical composition comprising the composition of claim 1 or at least one siRNA molecule of any one of claims 2 to 6 and a pharma- ceutically acceptable carrier.
8. 8. The pharmaceutical composition of claim 7, wherein the pharma- ceutically acceptable carrier comprises a lipid-based or polymer-based colloid.
9. 9. The pharmaceutical composition of claim 8, wherein the colloid is a liposome, a hydrogel, a microparticle, a nanoparticle, or a block copolymer micelle.
10. The siRNA molecule of claim 2 , wherein the siRNA molecule is formulated for intravenous, subcutaneous, or intrathecal administration.
11. A composition according to claim 1, a siRNA molecule according to any one of claims 2 to 6, or a pharmaceutical composition according to any one of claims 7 to 9 for use in the treatment of Alzheimer's disease or dementia.
12. A composition, siRNA molecule, or pharmaceutical composition for use as described in claim 11, which reduces accumulation of phosphorylated, aggregated human tau protein or inhibits expression of MSUT2 polynucleotide.
13. 12. The composition, siRNA molecule, or pharmaceutical composition for use according to claim 11, further comprising a cholinesterase inhibitor.
14. 14. The composition, siRNA molecule or pharmaceutical composition for use according to claim 13, wherein the cholinesterase inhibitor is galantamine, rivastigmine or donepezil.
15. 1. A method of inhibiting expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, the siRNA molecule comprising at least one sequence selected from the group consisting of SEQ ID NO:6-73, and wherein the siRNA molecule reduces accumulation of phosphorylated, aggregated tau.
16. 1. A method of inhibiting expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, the siRNA molecule comprising at least one sequence selected from the group consisting of SEQ ID NO:6-73, and wherein the siRNA molecule reduces accumulation of phosphorylated, aggregated tau.
17. 1. A method of enhancing a neuroinflammatory response to pathological tau protein, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-SEQ ID NO:5, SEQ ID NO:77 and SEQ ID NO:78, the siRNA molecule comprising a blunt-ended double-stranded structure of 25-28 nucleotides, the siRNA molecule comprising at least one sequence selected from the group consisting of SEQ ID NO:6-SEQ ID NO:73, and the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
18. 1. A method of reducing astrocytosis or microgliosis, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77 and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:6-73, and wherein the siRNA molecule reduces accumulation of phosphorylated, aggregated tau.
19. 1. A method of reducing neuroinflammation, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:1-5, SEQ ID NO:77, and SEQ ID NO:78, wherein the siRNA molecule comprises a blunt-ended double-stranded structure of 25-28 nucleotides, the siRNA molecule comprising at least one sequence selected from the group consisting of SEQ ID NO:6-73, and wherein the siRNA molecule reduces accumulation of phosphorylated, aggregated tau.
20. The method according to any one of claims 15 to 19, wherein the expression of the MSUT2 polynucleotide is inhibited or suppressed by the siRNA molecule by inhibiting binding of poly(A) RNA to the MSUT2 polynucleotide.
21. The method of any one of claims 15 to 19, wherein the cell is a mammalian cell.
22. 22. The method of claim 21 , wherein the mammalian cell is a brain cell.
23. The method of any one of claims 15 to 17, wherein at least one nucleotide of the siRNA molecule comprises a chemical modification.
24. 24. The method of claim 23, wherein the chemical modification is on the sense strand, the antisense strand, or on both strands.
25. The method of any one of claims 15 to 20, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO:
73.
26. the siRNA molecule is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64 20. The method of any one of claims 15 to 19, comprising or consisting of a sense strand comprising or consisting of at least one sequence selected from the group of SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72, and an antisense strand which is complementary to said sense strand selected from the group of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, and SEQ ID NO:73.
